(Q51814814)

13 April 2018

title

Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. (English)

1 reference

13 April 2018

0 references

G Klinger

1

1 reference

13 April 2018

D Frankenthal

2

1 reference

13 April 2018

P Merlob

3

1 reference

13 April 2018

G Diamond

4

1 reference

13 April 2018

L Sirota

5

1 reference

13 April 2018

R Levinson-Castiel

6

1 reference

13 April 2018

N Linder

7

1 reference

13 April 2018

B Stahl

8

1 reference

13 April 2018

D Inbar

9

1 reference

13 April 2018

publication date

10 February 2011

1 reference

13 April 2018

published in

Journal of Perinatology

1 reference

13 April 2018

volume

31

1 reference

13 April 2018

issue

9

1 reference

13 April 2018

page(s)

615-620

1 reference

13 April 2018

https://scigraph.springernature.com/pub.10.1038/jp.2010.211

exact match

0 references

cites work

Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Safety of selective serotonin reuptake inhibitors in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Developmental effects of SSRIs: lessons learned from animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Neurodevelopment of children exposed in utero to antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Reliability and stability of the Denver Developmental Screening Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Maternal anxiety, mother-infant interactions, and infants' response to challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Maternal depression and anxiety across the postpartum year and infant social engagement, fear regulation, and stress reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Maternal psychological distress and fetal growth trajectories: the Generation R Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Trait anxiety in pregnant women predicts offspring birth outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

Increasing use of antidepressants in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

7 January 2021

Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

7 January 2021

Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

7 January 2021

Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications

1 reference

https://api.crossref.org/works/10.1038%2FJP.2010.211

7 January 2021

Identifiers

DOI

10.1038/JP.2010.211

1 reference

13 April 2018

1 reference

13 April 2018